Evaluation of tumor response to combination therapy of Nivolumab and Ipilumab verusus monotherapy of either Nivolumab or Pembrolizumab in melanoma patients by analyzing T cell exhaustion marker as predictor of response

Trial Profile

Evaluation of tumor response to combination therapy of Nivolumab and Ipilumab verusus monotherapy of either Nivolumab or Pembrolizumab in melanoma patients by analyzing T cell exhaustion marker as predictor of response

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2016

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 22 Jul 2016 New trial record
    • 07 Jun 2016 Results (n=53) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top